Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [08/19/2026 16:11 PDT] Ocugen, Inc. (NASDAQ:OCGN), Up By 100% ($1.24) From $1.24 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [08/13/2026 06:00 PDT] OCGN Expected to Trade Up After Bullish Patterns Develop
• [08/03/2026 05:49 PDT] OCGN Expected to Trade Up After Bullish Patterns Develop
• [06/30/2026 07:46 PDT] OCGN Expected to Trade Up After Bullish Patterns Develop
• [06/26/2026 21:21 PDT] Market Maker Surveillance Report. OCGN, Highest Net Buy Volume With Lowest Price Friction For Friday, June 26th 2026
• [06/26/2026 12:42 PDT] Ocugen, Inc. (NASDAQ:OCGN), Up By 100% ($1.27) From $1.27 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [06/24/2026 12:42 PDT] Ocugen, Inc. (NASDAQ:OCGN), Up By 100% ($1.27) From $1.27 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [06/22/2026 06:39 PDT] OCGN Expected to Trade Up After Bullish Patterns Develop